Related Experiment Videos
Reduced histone deacetylase in COPD: clinical implications
1National Heart and Lung Institute, Imperial College School of Medicine, Dovehouse St, London SW3 6LY, UK. p.j.barnes@imperial.ac.uk
Chest
|January 21, 2006
Summary
Histone deacetylase-2 (HDAC-2) reduction in COPD amplifies inflammation and corticosteroid resistance. Restoring HDAC-2 activity via antioxidants or theophylline may improve treatment sensitivity in COPD and related inflammatory lung diseases.
Area of Science:
- Pulmonary Medicine
- Molecular Biology
- Inflammation Research
Background:
- Chronic Obstructive Pulmonary Disease (COPD) involves progressive airway and lung inflammation driven by inflammatory gene expression.
- Inflammatory gene regulation occurs via histone acetylation/deacetylation; histone deacetylases (HDACs) suppress this expression.
- HDAC activity, specifically HDAC-2, is diminished in COPD lungs, exacerbating inflammation and corticosteroid resistance.
Purpose of the Study:
- To investigate the role of HDAC-2 reduction in COPD pathogenesis and corticosteroid resistance.
- To explore potential therapeutic strategies targeting HDAC-2 activity for COPD treatment.
Main Methods:
- Analysis of HDAC expression and activity in COPD patient lung tissue and alveolar macrophages.
- Investigation of the impact of oxidative and nitrative stress on HDAC-2 levels.
- Assessment of the effects of antioxidants, nitric oxide synthesis inhibitors, and theophylline on corticosteroid sensitivity.
Main Results:
- Reduced HDAC-2 expression and activity were observed in COPD lungs, correlating with disease progression.
- Oxidative and nitrative stress in COPD lungs were identified as factors contributing to HDAC-2 reduction.
- Antioxidants, nitric oxide inhibitors, and theophylline (an HDAC activator) demonstrated potential to restore corticosteroid sensitivity.
Conclusions:
- Reduced HDAC-2 is a key mechanism underlying COPD inflammation and corticosteroid resistance.
- Therapeutic strategies aimed at increasing HDAC-2 activity, such as theophylline or antioxidants, may offer new avenues for COPD treatment.
- The findings are also relevant to other conditions with increased oxidative stress, including smoking asthmatics, severe asthma, and cystic fibrosis.